A medication designed to assist with walking for individuals living with multiple sclerosis (MS) is now available through NHS England. Fampridine, which functions by boosting nerve signals, has been introduced as a treatment option for patients who meet specific criteria regarding the severity of their mobility challenges.
Eligibility and Treatment Process
While there are more than 120,000 people living with MS in England, the new treatment is not intended for all patients. NHS officials estimate that approximately 5,000 people per year will be eligible for the drug, based on the extent of their walking difficulties.
The rollout includes a strict assessment period to ensure the medication is effective for the individual. Patients will be prescribed the medicine for an initial trial period of up to one month. Continued access to the drug will be restricted to those who demonstrate a “clear benefit” during this time.
Clinical and Patient Perspectives
Health officials have expressed optimism regarding the impact of the drug. Prof Frankie Swords, the NHS national medical director, stated that walking difficulties significantly affect the freedom and independence of MS patients. Swords described the pill as a signal-boosting
medication that could be life-changing for thousands of patients,
noting that even modest improvements could help patients move around their homes more easily and live with greater independence.
Patient groups have also welcomed the development. Ceri Smith, representing the MS Society, noted that the organization is “delighted” by the news, emphasizing that the drug could allow individuals to live more independently or maintain employment.
For some, the availability of the drug on the NHS addresses a significant financial barrier. Aysen Slack, a 65-year-old from Eastbourne, previously paid privately for the medication. She reported that while the drug was “working well,” the significant expense
made it unsustainable to maintain long-term. Slack, who currently relies on sticks to move around her flat, described the announcement as “great news” and stated she would definitely like to try the medication again through the NHS to improve her walking ability.
Summary of Treatment Criteria
| Factor | Details |
|---|---|
| Target Population | People with MS experiencing walking difficulties |
| Estimated Annual Eligibility | Approximately 5,000 patients |
| Trial Period | Up to one month |
| Continuation Requirement | Demonstration of “clear benefit” |
Context and Potential Impact
The introduction of fampridine represents a move to support patients who face mobility constraints that limit their daily activities and confidence. By focusing on patients who show measurable progress during the initial trial phase, the NHS aims to target the treatment toward those who will derive the most meaningful improvement in their quality of life.
As noted by Prof Swords, the goal of the treatment is to provide patients with the ability to go out with greater confidence and manage daily tasks more effectively. With the drug now integrated into the public health system, patients like Slack, who previously faced the burden of private costs, gain a new avenue to manage the physical challenges associated with their condition.
